Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Cyclo Therapeutics stock (Cyclo Therapeutics)

Buy Cyclo Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Cyclo Therapeutics stock is currently available to purchase as an over-the-counter (OTC) stock on the OTCQB. But many popular brokerages don't offer access to OTC stocks.

Cyclo has recently filed with the SEC to list stock on the Nasdaq Capital Market. This will make it possible to buy its stock from any major stock broker.

Our top picks for where to buy Cyclo Therapeutics stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Complimentary access to a financial planner

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

How to buy Cyclo Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CTDH. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Cyclo Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cyclo Therapeutics stock price (OTCQB: CTDH)

Use our graph to track the performance of CTDH stocks over time.

Cyclo Therapeutics shares at a glance

Information last updated 2021-01-22.
52-week range$0.00 - $0.00
50-day moving average $6.10
200-day moving average $10.34
Wall St. target price$1.25
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-0.06

Is it a good time to buy Cyclo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyclo Therapeutics financials

Revenue TTM $985,153
Gross profit TTM $769,638
Return on assets TTM -111.53%
Return on equity TTM 0%
Profit margin 0%
Book value $0.03
Market Capitalization $146,185

TTM: trailing 12 months

Cyclo Therapeutics share dividends

We're not expecting Cyclo Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Have Cyclo Therapeutics's shares ever split?

Cyclo Therapeutics's shares were split on a 1:100 basis on 8 December 2020 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyclo Therapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Cyclo Therapeutics shares which in turn could have impacted Cyclo Therapeutics's share price.

Cyclo Therapeutics share price volatility

Over the last 12 months, Cyclo Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while Cyclo Therapeutics's is -0.8845. This would suggest that Cyclo Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cyclo Therapeutics has bucked the trend.

To put Cyclo Therapeutics's beta into context you can compare it against those of similar companies.

Cyclo Therapeutics overview

Cyclo Therapeutics, Inc. , a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc.

Frequently asked questions

null
What percentage of Cyclo Therapeutics is owned by insiders or institutions?
Currently 1.019% of Cyclo Therapeutics shares are held by insiders and 0.102% by institutions.
How many people work for Cyclo Therapeutics?
Latest data suggests 5 work at Cyclo Therapeutics.
When does the fiscal year end for Cyclo Therapeutics?
Cyclo Therapeutics's fiscal year ends in December.
Where is Cyclo Therapeutics based?
Cyclo Therapeutics's address is: 6714 NW 16th Street, Gainesville, FL, United States, 32563
What is Cyclo Therapeutics's ISIN number?
Cyclo Therapeutics's international securities identification number is: US23254X1028
What is Cyclo Therapeutics's CUSIP number?
Cyclo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 23254X102

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site